NCT01718743View on ClinicalTrials.gov

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2012

Primary Completion Date

April 12, 2023

Study Completion Date

April 12, 2023

Conditions

Hematopoietic Cell Transplantation RecipientPlasma Cell Myeloma

Interventions

DRUG

Ixazomib Citrate

Given PO

DRUG

Lenalidomide

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01718743 - Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter